Form 4: Sutro Biopharma CEO Buys 12,500 Shares

Sutro Biopharma's CEO, Jane Chung, acquired 12,500 shares of common stock at $0.8009 per share, increasing her direct beneficial ownership to 122,850 shares.

Summary

• Jane Chung, the Chief Executive Officer and a Director of Sutro Biopharma, Inc. (STRO), purchased 12,500 shares of the company's common stock.
• The transaction occurred on October 15, 2025, at a price of $0.8009 per share.
• Following this acquisition, Ms. Chung's direct beneficial ownership in Sutro Biopharma, Inc. stands at 122,850 shares of common stock.
• The transaction was made pursuant to a Rule 10b5-1 trading plan, indicating a pre-arranged purchase.

Sentiment

Score: 8

Explanation: The sentiment is positive due to the CEO's direct purchase of company stock, signaling strong confidence in the company's future value and performance.

Positives

• The Chief Executive Officer's purchase of company stock signals confidence in the future performance and valuation of Sutro Biopharma, Inc.
• The acquisition was executed under a Rule 10b5-1 plan, suggesting a planned investment strategy by management.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance, but the insider purchase by the CEO can be interpreted as a positive outlook on the company's future prospects.

Industry Context

Insider buying, particularly by a CEO, is often viewed by the market as a strong indicator of management's belief in the company's undervalued stock or strong future performance. In the biopharma sector, such signals can be particularly impactful given the long development cycles and binary outcomes of clinical trials.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive signal, potentially increasing investor confidence and demand for the stock.
• Employees might perceive this as a sign of stability and positive future prospects for the company.

Key Dates

Recommendation

The Chief Executive Officer's direct purchase of 12,500 shares at $0.8009 per share, especially under a Rule 10b5-1 plan, is a strong signal of management's confidence in Sutro Biopharma's future. Insider buying, particularly from top executives, often precedes positive company developments or reflects a belief that the stock is undervalued. This action suggests a favorable outlook from a key decision-maker, making it a compelling 'buy' signal for investors.

Keywords

Sutro Biopharma, STRO, Insider Buy, Jane Chung, CEO, Stock Purchase, Form 4, Biopharma